Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cusatuzumab ...Middle East

ZUG, Switzerland, June 7, 2021 /PRNewswire/ -- Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today its decision not to continue the collaboration and license agreement with argenx for cusatuzumab, an investigational therapeutic...

Hence then, the article about janssen affiliate cilag gmbh international discontinues collaboration and license agreement with argenx for cusatuzumab was published today ( Monday 07/06/2021 - 08:45 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cusatuzumab )

Also on site :

• ‘90s Rocker Announces Book Tour in Support of ‘Refreshingly Pure of Heart’ Memoir
• 'Dancing With the Stars' Tour Forced to Reschedule Show Due to Impending Snowstorm
• Robert Reed’s Daughter, Who Appeared on 'The Brady Bunch', Dies at 69